

Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/O863BBFFA4F7EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: O863BBFFA4F7EN

Abstracts

The 7 major open angle glaucoma markets reached a value of US\$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 7.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.69% during 2024-2034.

The open angle glaucoma market has been comprehensively analyzed in IMARC's new report titled "Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Open angle glaucoma refers to a chronic, irreversible, and progressive multifactorial optic neuropathy in which the pressure inside the eye increases. It is mainly characterized by an open angle of the anterior chamber, changes to the optic nerve head, and progressive loss of peripheral vision, followed by the loss of the central visual field. There aren't any noticeable indications of this ailment in the early stage, but in the advanced stage, the condition manifests as reduced vision, eye pain or pressure, a swollen or bulging cornea, redness in the white of the eye, rainbow-colored halos around lights, headaches, nausea, vomiting, etc. The diagnosis of open angle glaucoma typically requires a combination of the patient's clinical features, medical history, and eye examination. Other common assessment tools utilized to confirm a diagnosis include pachymetry, slit-lamp exam, gonioscopy, visual field and visual acuity tests, etc. The healthcare provider may also perform optical coherence tomography to detect changes in the optic nerve that may cause the disease.

The rising cases of eye disorders, which increase resistance in the drainage canals and damage the optic nerve, are primarily driving the open angle glaucoma market. Besides this, the growing prevalence of several associated risk factors, including advanced age,

family history, obesity, systemic diseases like diabetes and hypertension, etc., is also augmenting the market growth. Furthermore, the widespread adoption of effective medications, such as alpha-2 adrenergic agonists and carbonic anhydrase inhibitors, which decrease aqueous production and enhance uveoscleral outflow, thereby providing symptom relief, is creating a positive outlook for the market. Apart from this, the inflating utilization of minimally invasive glaucoma surgery (MIGS), owing to its numerous advantages, including improved outflow of fluid from the eye and faster recovery with potentially fewer side effects than traditional surgeries, is acting as another significant growth-inducing factor. Moreover, the emerging popularity of bimatoprost intracameral implant for treating the ailment, since it releases drugs directly to the targeted tissues and lowers intraocular pressure among patients, is expected to drive the open angle glaucoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the open angle glaucoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for open angle glaucoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the open angle glaucoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the open angle glaucoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the open angle glaucoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current open angle glaucoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the open angle glaucoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the open angle glaucoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the open angle glaucoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (?2018-2034?) of open angle glaucoma across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of open angle glaucoma by age across the seven major markets?

What is the number of prevalent cases (?2018-2034?) of open angle glaucoma by gender across the seven major markets?

How many patients are diagnosed (?2018-2034?) with open angle glaucoma across the seven major markets?

What is the size of the open angle glaucoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of open angle glaucoma?

What will be the growth rate of patients across the seven major markets?

Open Angle Glaucoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for open angle glaucoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the open angle glaucoma market?

What are the key regulatory events related to the open angle glaucoma market?

What is the structure of clinical trial landscape by status related to the open angle glaucoma market?

What is the structure of clinical trial landscape by phase related to the open angle glaucoma market?

What is the structure of clinical trial landscape by route of administration related to the open angle glaucoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 OPEN ANGLE GLAUCOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 OPEN ANGLE GLAUCOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 OPEN ANGLE GLAUCOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (?2018-2034?)

- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 OPEN ANGLE GLAUCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 OPEN ANGLE GLAUCOMA - UNMET NEEDS

10 OPEN ANGLE GLAUCOMA - KEY ENDPOINTS OF TREATMENT

11 OPEN ANGLE GLAUCOMA - MARKETED PRODUCTS

- 11.1 List of Open Angle Glaucoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Rocklatan (Latanoprost/netarsudil) - Alcon
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Durysta (Bimatoprost sustained-release) - AbbVie
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Lumigan (Bimatoprost) - AbbVie
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Vyzulta (Latanoprostene bunod) - Bausch & Lomb
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Rescula (Unoprostone) - R-Tech Ueno Ltd
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 OPEN ANGLE GLAUCOMA - PIPELINE DRUGS

- 12.1 List of Open Angle Glaucoma Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 NCX 470 - NicOx
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 STN1012600 - Santen Pharmaceutical
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 DE-130A - Santen SAS
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status
- 12.1.4 QLS 101 - Qlaris bio
 - 12.1.4.1 Drug Overview
 - 12.1.4.2 Mechanism of Action
 - 12.1.4.3 Clinical Trial Results
 - 12.1.4.4 Safety and Efficacy
 - 12.1.4.5 Regulatory Status
- 12.1.5 ONL1204 - ONL Therapeutics
 - 12.1.5.1 Drug Overview
 - 12.1.5.2 Mechanism of Action
 - 12.1.5.3 Clinical Trial Results
 - 12.1.5.4 Safety and Efficacy
 - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. OPEN ANGLE GLAUCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. OPEN ANGLE GLAUCOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 OPEN ANGLE GLAUCOMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Open Angle Glaucoma - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Open Angle Glaucoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Open Angle Glaucoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Open Angle Glaucoma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Open Angle Glaucoma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Open Angle Glaucoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Open Angle Glaucoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Open Angle Glaucoma - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Open Angle Glaucoma - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Open Angle Glaucoma - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Open Angle Glaucoma - Access and Reimbursement Overview

16 OPEN ANGLE GLAUCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 OPEN ANGLE GLAUCOMA MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 OPEN ANGLE GLAUCOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Open Angle Glaucoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/O863BBFFA4F7EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O863BBFFA4F7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

